Global Infectious Diseases Therapeutics Market - Influenza, RSV, Chlamydia, and Gonorrhoea

Persistent Unmet Need for Treatment Fuels Novel Antiviral/Antibacterial Drug Development

Regular Price: USD 3,950

Special Price USD 3,555

10% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 3,555

PAY BY INVOICE

Be the first to review this product

This research service focuses on antibiotic/antibacterial therapeutics for the treatment of infection by blood-borne (sexually transmitted) bacteria, which include Chlamydia trachomatis and Neisseria gonorrhoea as well as antiviral therapeutics for infections by vector-borne pathogens such as the influenza virus and the human respiratory syncytial virus (RSV).This research service comprises of a product and pipeline assessment for marketed and investigational products and combination regimens for the treatment of Chlamydia trachomatis, Neisseria gonorrhoeae, Influenza and RSV infections. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines, results, and epidemiology.

Table of Contents

Executive SummaryIntroductionIntroduction (continued)Evolution of Standard of CareEvolution of Standard of Care (continued)Evolution of Standard of Care (continued)Evolution of Standard of Care (continued)Methodology and ScopeMarket OverviewMarket Overview—SegmentationMarket Overview—Segmentation (continued)Market Overview—Segmentation (continued)Market Overview—Segmentation (continued)Market Overview—Segmentation (continued)RSV Therapeutics MarketRSV—Market SegmentationRSV—Competitive Landscape: Select Marketed Products and Products in DevelopmentRSV—Key Marketed Products SynopsisRSV Product DashboardRSV Product Dashboard (continued)RSV—Pipeline SynopsisRSV—Pipeline Synopsis (continued)RSV—Major Ongoing/Recently Completed Clinical Trials RSV—Major Ongoing/Recently Completed Clinical Trials (continued) RSV—Major Ongoing/Recently Completed Clinical Trials (continued) RSV—Major Ongoing/Recently Completed Clinical Trials Detailed FindingsRSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)RSV—Timeline of Key EventsRSV—Key Company to Watch RSV—Key Companies with Best PracticesRSV—New Market OpportunitiesRSV—New Market Opportunities (continued)RSV—Merger, Acquisition, and Partnership AssessmentInfluenza Therapeutics MarketInfluenza—Market SegmentationInfluenza—Competitive Landscape: Select Marketed Products and Products in DevelopmentInfluenza Antiviral SegmentInfluenza Antivirals—Key Marketed Products SynopsisInfluenza Antivirals—Key Marketed Products Synopsis (continued)Influenza Antivirals—Key Marketed Products Synopsis (continued)Influenza Antivirals—Product DashboardInfluenza Antivirals—Product Dashboard (continued)Influenza Antivirals—Product Dashboard (continued)Influenza Antivirals—Pipeline SynopsisInfluenza Antivirals—Pipeline Synopsis (continued)Influenza Antivirals—Pipeline Synopsis (continued)Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials (continued)Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed FindingsInfluenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Influenza Antivirals—Timeline of Key EventsInfluenza Vaccines SegmentInfluenza Vaccines—Key Marketed Products SynopsisInfluenza Vaccines—Key Marketed Products Synopsis (continued)Influenza Vaccines—Key Marketed Products Synopsis (continued)Influenza Vaccines—Key Marketed Products Synopsis (continued)Influenza Vaccines—Key Marketed Products Synopsis (continued)Influenza Vaccines—Key Marketed Products Synopsis (continued)Influenza Vaccines—Pipeline SynopsisInfluenza Vaccines—Pipeline Synopsis (continued)Influenza Vaccines—Pipeline Synopsis (continued)Influenza Vaccines—Pipeline Synopsis (continued)Influenza Vaccines—Key Companies to Watch Influenza Vaccines—Merger, Acquisition and Partnership AssessmentInfluenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)Influenza Vaccines—Merger, Acquisition and Partnership AssessmentInfluenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)Chlamydia Therapeutics MarketChlamydia—Market SegmentationChlamydia—Treatment RegimenChlamydia—Treatment Regimen (continued)Chlamydia—Treatment Regimen (continued)Chlamydia—Competitive Landscape: Select Marketed Products and Products in DevelopmentChlamydia—Key Marketed Products SynopsisChlamydia—Key Marketed Products Synopsis (continued)Chlamydia—Pipeline SynopsisChlamydia—Major Ongoing/Recently Completed Clinical TrialsChlamydia—Major Ongoing/Recently Completed Clinical Trials (continued)Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed FindingsChlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)Chlamydia—Timeline of Key EventsChlamydia—Key Company to Watch Gonorrhoea Therapeutic MarketGonorrhoea—Market SegmentationGonorrhoea—Treatment RegimenGonorrhoea—Treatment Regimen (continued)Gonorrhoea—Treatment Regimen (continued)Gonorrhoea—Treatment Regimen (continued)Gonorrhoea—Competitive Landscape: Select Marketed Products and Products in DevelopmentGonorrhoea—Key Marketed Products SynopsisGonorrhoea—Key Marketed Products Synopsis (continued)Gonorrhoea—Key Marketed Products Synopsis (continued)Gonorrhoea—Key Marketed Products Synopsis (continued)Gonorrhoea—Pipeline SynopsisGonorrhoea—Pipeline Synopsis (continued)Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials Detailed Findings Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued) Gonorrhoea—Timeline of Key EventsGonorrhoea—Key Company to Watch Legal DisclaimerAppendixDisease Characteristics Disease Characteristics (continued) Disease Characteristics (continued) Disease Characteristics (continued) The Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.